The subsequent KEYNOTE-042 study assessed pembrolizumab or platinum-based chemotherapy in treatment naïve advanced NSCLC patients with PD-L1 TPS ≥ 1%, and similarly found that pembrolizumab provided greater survival benefit, driven largely by those with TPS scores ≥50% [67]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.